{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"14.900","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"446,466,350","primaryexch":"HKEX","ric":"2105.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BN95XV8","am":"178.93","iv":"","ew_strike":"","as":"14.890","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"14.880","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-26 10:38:37.0","lo52":"4.440","shares_issued_date":"17 Sep 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Lu Chris Xiangyang","underlying_ric":"2105.HK","hi52":"23.500","issuer_name":"Laekna, Inc. - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"12.760","mkt_cap":"6.64","f_aum_hkd":null,"ew_sub_per_to":"","ls":"14.880","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"+2.060","aum":"","issued_shares_class_B":null,"vo":"12.65","secondary_listing_flag":false,"listing_date":"29 Jun 2023","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Laekna, Inc. - B","nm_s":"LAEKNA-B","sym":"2105","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.","op":"12.870","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"46F, Hopewell Centre<br/>183 Queen's Road East<br/>Wan Chai<br/>Hong Kong","pc":"+16.07","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"12.820","isin":"KYG5340S1093","moneyness":""}},"qid":"1758890088383"}
